GSK Plc and CureVac NV are planning further patient trials of their messenger RNA vaccines for flu and Covid-19 after promising early results, though the partners still lag behind rivals in the race to expand use of mRNA technology.
(Bloomberg) — GSK Plc and CureVac NV are planning further patient trials of their messenger RNA vaccines for flu and Covid-19 after promising early results, though the partners still lag behind rivals in the race to expand use of mRNA technology.
The partners’ second-generation vaccine candidates showed promising abilities to spur the immune system in early-stage trials, CureVac said on Friday. The companies plan to start a mid-stage trial of the Covid vaccine later this year, targeting the most relevant variant, while a seasonal flu study to target four different strains should begin around mid-year, CureVac said.
The results will enable CureVac to “turn the page and enter 2023 as a competitive player in the development of mRNA therapies,” Chief Executive Officer Franz-Werner Haas said in a statement.
CureVac shares rose 12% in pre-market trading at 8:22 a.m. in New York. GSK shares were little changed in London.
Despite being one of the first companies to start work on mRNA vaccines, CureVac fell behind rivals BioNTech SE and Moderna Inc. The German biotech had a slower development timeline on its first-generation Covid vaccine and then had to abandon that candidate in 2021 after disappointing clinical trial results.
CureVac’s initial shot was different from that of competitors because it used an unmodified form of mRNA. Both candidates now being pushed forward in clinical trials use modified mRNA.
GSK is funding research and development for the flu program, while both partners contribute to the Covid project. At the end of the third quarter, CureVac had 540.9 million euros ($568 million) in cash, enough to fund itself through the end of this year.
–With assistance from Lisa Pham.
(Updates share prices. A previous version of this story corrected the company’s earlier statements on timing of future trials in deck headlines and second paragraph)
More stories like this are available on bloomberg.com
©2023 Bloomberg L.P.